Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Mar;64(Suppl 2):ii74–ii77. doi: 10.1136/ard.2004.030783

Psoriatic arthritis therapy: NSAIDs and traditional DMARDs

P Nash, D Clegg
PMCID: PMC1766880  PMID: 15708943

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) and traditional disease modifying antirheumatic drugs (DMARDs) are widely used in the treatment of psoriatic arthritis (PsA), but this is based more upon clinical experience than adequate evidence from clinical trials. This report summarises the results from available trials highlighting evidence of efficacy and deficiencies with respect to effect on joints and to a lesser degree cutaneous disease. The available published data on efficacy of NSAIDs, glucocorticoids, antimalarials, sulfasalazine, gold, methotrexate, azathioprine, and ciclosporin are detailed, as well as new data on leflunomide and other novel agents. The conclusions of this review are that evidence supports marginal efficacy of sulfasalazine and perhaps gold in the treatment of peripheral psoriatic arthropathy, and methotrexate and ciclosporin are effective for treating the skin disease although evidence for improvement of the arthropathy is empirical at best. New trials with standardised and validated outcome measures are required to better assess efficacy. Evaluating newer agents, against and in combination with traditional DMARDS, may further clarify the latter's role in the future management of this condition.

Full Text

The Full Text of this article is available as a PDF (61.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abu-Shakra M., Gladman D. D., Thorne J. C., Long J., Gough J., Farewell V. T. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol. 1995 Feb;22(2):241–245. [PubMed] [Google Scholar]
  2. BLACK R. L., O'BRIEN W. M., VANSCOTT E. J., AUERBACH R., EISEN A. Z., BUNIM J. J. METHOTREXATE THERAPY IN PSORIATIC ARTHRITIS; DOUBLE-BLIND STUDY ON 21 PATIENTS. JAMA. 1964 Sep 7;189:743–747. [PubMed] [Google Scholar]
  3. Baker H., Ryan T. J. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol. 1968 Dec;80(12):771–793. doi: 10.1111/j.1365-2133.1968.tb11947.x. [DOI] [PubMed] [Google Scholar]
  4. Baum J., Hurd E., Lewis D., Ferguson J. L., Ziff M. Treatment of psoriatic arthritis with 6-mercaptopurine. Arthritis Rheum. 1973 Mar-Apr;16(2):139–147. doi: 10.1002/art.1780160202. [DOI] [PubMed] [Google Scholar]
  5. Bellamy N. Science of assessment. Ann Rheum Dis. 2005 Mar;64 (Suppl 2):ii42–ii45. doi: 10.1136/ard.2004.031567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ben-Chetrit E., Rubinow A. Exacerbation of psoriasis by ibuprofen. Cutis. 1986 Jul;38(1):45–45. [PubMed] [Google Scholar]
  7. Carette S., Calin A., McCafferty J. P., Wallin B. A. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis. Arthritis Rheum. 1989 Feb;32(2):158–165. doi: 10.1002/anr.1780320208. [DOI] [PubMed] [Google Scholar]
  8. Clark David Walter John, Coulter David Morris. Psoriasis associated with rofecoxib. Arch Dermatol. 2003 Sep;139(9):1223–1223. doi: 10.1001/archderm.139.9.1223. [DOI] [PubMed] [Google Scholar]
  9. Clegg D. O., Reda D. J., Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999 Nov;42(11):2325–2329. doi: 10.1002/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  10. Clegg D. O., Reda D. J., Mejias E., Cannon G. W., Weisman M. H., Taylor T., Budiman-Mak E., Blackburn W. D., Vasey F. B., Mahowald M. L. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996 Dec;39(12):2013–2020. doi: 10.1002/art.1780391210. [DOI] [PubMed] [Google Scholar]
  11. Combe B., Goupille P., Kuntz J. L., Tebib J., Lioté F., Bregeon C. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol. 1996 Jul;35(7):664–668. doi: 10.1093/rheumatology/35.7.664. [DOI] [PubMed] [Google Scholar]
  12. Dorwart B. B., Gall E. P., Schumacher H. R., Krauser R. E. Chrysotherapy in psoriatic arthritis. Efficacy and toxicity compared to rheumatoid arthritis. Arthritis Rheum. 1978 Jun;21(5):513–515. doi: 10.1002/art.1780210504. [DOI] [PubMed] [Google Scholar]
  13. Dougados M., vam der Linden S., Leirisalo-Repo M., Huitfeldt B., Juhlin R., Veys E., Zeidler H., Kvien T. K., Olivieri I., Dijkmans B. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995 May;38(5):618–627. doi: 10.1002/art.1780380507. [DOI] [PubMed] [Google Scholar]
  14. Espinoza L. R., Zakraoui L., Espinoza C. G., Gutiérrez F., Jara L. J., Silveira L. H., Cuéllar M. L., Martínez-Osuna P. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol. 1992 Jun;19(6):872–877. [PubMed] [Google Scholar]
  15. Farr M., Kitas G. D., Waterhouse L., Jubb R., Felix-Davies D., Bacon P. A. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol. 1990 Feb;29(1):46–49. doi: 10.1093/rheumatology/29.1.46. [DOI] [PubMed] [Google Scholar]
  16. Fox R. I. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl. 1998 Jul;53:20–26. [PubMed] [Google Scholar]
  17. Fraser S. M., Hopkins R., Hunter J. A., Neumann V., Capell H. A., Bird H. A. Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol. 1993 Oct;32(10):923–925. doi: 10.1093/rheumatology/32.10.923. [DOI] [PubMed] [Google Scholar]
  18. Gladman D. D., Blake R., Brubacher B., Farewell V. T. Chloroquine therapy in psoriatic arthritis. J Rheumatol. 1992 Nov;19(11):1724–1726. [PubMed] [Google Scholar]
  19. Goupille P., Soutif D., Valat J. P. Treatment of psoriatic arthropathy. Semin Arthritis Rheum. 1992 Jun;21(6):355–367. doi: 10.1016/0049-0172(92)90036-d. [DOI] [PubMed] [Google Scholar]
  20. Gupta A. K., Grober J. S., Hamilton T. A., Ellis C. N., Siegel M. T., Voorhees J. J., McCune W. J. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol. 1995 May;22(5):894–898. [PubMed] [Google Scholar]
  21. Gómez-Vaquero C., Rodríguez-Moreno J., Ros S., Marcos R., Fiter J., Roig-Escofet D. Termination of disease-modifying drugs in psoriatic arthritis: study of 109 courses of treatment. Br J Rheumatol. 1996 Jun;35(6):564–567. doi: 10.1093/rheumatology/35.6.564. [DOI] [PubMed] [Google Scholar]
  22. Husted J. A., Gladman D. D., Farewell V. T., Cook R. J. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001 Apr;45(2):151–158. doi: 10.1002/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  23. Kaltwasser J. Peter, Nash Peter, Gladman Dafna, Rosen Cheryl F., Behrens Frank, Jones Peter, Wollenhaupt Jürgen, Falk Franziska G., Mease Philip, Treatment of Psoriatic Arthritis Study Group Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004 Jun;50(6):1939–1950. doi: 10.1002/art.20253. [DOI] [PubMed] [Google Scholar]
  24. Klinkhoff A. V., Gertner E., Chalmers A., Gladman D. D., Stewart W. D., Schachter G. D., Schachter R. K. Pilot study of etretinate in psoriatic arthritis. J Rheumatol. 1989 Jun;16(6):789–791. [PubMed] [Google Scholar]
  25. Lacaille D., Stein H. B., Raboud J., Klinkhoff A. V. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate? J Rheumatol. 2000 Aug;27(8):1922–1927. [PubMed] [Google Scholar]
  26. Mader R., Gladman D. D., Long J., Gough J., Farewell V. T. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Invest Med. 1995 Apr;18(2):139–143. [PubMed] [Google Scholar]
  27. Maksymowych Walter P., Inman Robert D., Gladman Dafna, Thomson Glen, Stone Millicent, Karsh Jacob, Russell Anthony S., Spondyloarthritis Research Consortium of Canada (SPARCC) Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol. 2003 Jun;30(6):1356–1363. [PubMed] [Google Scholar]
  28. Matucci-Cerinic M., Lotti T., Cappugi P., Boddi V., Fattorini L., Panconesi E. Somatostatin treatment of psoriatic arthritis. Int J Dermatol. 1988 Jan-Feb;27(1):56–58. doi: 10.1111/j.1365-4362.1988.tb02341.x. [DOI] [PubMed] [Google Scholar]
  29. Mazzanti G., Coloni L., De Sabbata G., Paladini G. Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study. Acta Derm Venereol Suppl (Stockh) 1994;186:116–117. [PubMed] [Google Scholar]
  30. McKendry R. J., Kraag G., Seigel S., al-Awadhi A. Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis. Ann Rheum Dis. 1993 Nov;52(11):826–828. doi: 10.1136/ard.52.11.826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Mease P. J., Antoni C. E., Gladman D. D., Taylor W. J. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005 Mar;64 (Suppl 2):ii49–ii54. doi: 10.1136/ard.2004.034165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mease P. J., Antoni C. E. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis. 2005 Mar;64 (Suppl 2):ii78–ii82. doi: 10.1136/ard.2004.034157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Meyerhoff J. O. Exacerbation of psoriasis with meclofenamate. N Engl J Med. 1983 Aug 25;309(8):496–496. doi: 10.1056/NEJM198308253090817. [DOI] [PubMed] [Google Scholar]
  34. Palit J., Hill J., Capell H. A., Carey J., Daunt S. O., Cawley M. I., Bird H. A., Nuki G. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol. 1990 Aug;29(4):280–283. doi: 10.1093/rheumatology/29.4.280. [DOI] [PubMed] [Google Scholar]
  35. Price R., Gibson T. D-penicillamine and psoriatic arthropathy. Br J Rheumatol. 1986 May;25(2):228–228. doi: 10.1093/rheumatology/25.2.228. [DOI] [PubMed] [Google Scholar]
  36. Rahman P., Gladman D. D., Cook R. J., Zhou Y., Young G. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol. 1998 Oct;25(10):1957–1961. [PubMed] [Google Scholar]
  37. Rahman P., Nguyen E., Cheung C., Schentag C. T., Gladman D. D. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol. 2001 May;28(5):1041–1044. [PubMed] [Google Scholar]
  38. Sarzi-Puttini P., Santandrea S., Boccassini L., Panni B., Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol. 2001;19(1 Suppl 22):S17–S20. [PubMed] [Google Scholar]
  39. Seideman P., Fjellner B., Johannesson A. Psoriatic arthritis treated with oral colchicine. J Rheumatol. 1987 Aug;14(4):777–779. [PubMed] [Google Scholar]
  40. Spadaro A., Riccieri V., Sili-Scavalli A., Sensi F., Taccari E., Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol. 1995 Sep-Oct;13(5):589–593. [PubMed] [Google Scholar]
  41. Steinsson K., Jónsdóttir I., Valdimarsson H. Cyclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis. 1990 Aug;49(8):603–606. doi: 10.1136/ard.49.8.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Vahlquist C., Larsson M., Ernerudh J., Berlin G., Skogh T., Vahlquist A. Treatment of psoriatic arthritis with extracorporeal photochemotherapy and conventional psoralen-ultraviolet A irradiation. Arthritis Rheum. 1996 Sep;39(9):1519–1523. doi: 10.1002/art.1780390911. [DOI] [PubMed] [Google Scholar]
  43. Wahba A., Cohen H. Therapeutic trials with oral colchicine in psoriasis. Acta Derm Venereol. 1980;60(6):515–520. [PubMed] [Google Scholar]
  44. Wilfert H., Hönigsmann H., Steiner G., Smolen J., Wolff K. Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol. 1990 Feb;122(2):225–232. doi: 10.1111/j.1365-2133.1990.tb08269.x. [DOI] [PubMed] [Google Scholar]
  45. Willkens R. F., Williams H. J., Ward J. R., Egger M. J., Reading J. C., Clements P. J., Cathcart E. S., Samuelson C. O., Jr, Solsky M. A., Kaplan S. B. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984 Apr;27(4):376–381. doi: 10.1002/art.1780270403. [DOI] [PubMed] [Google Scholar]
  46. Wollina U., Ständer K., Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis--short- and long-term toxicity in 104 patients. Clin Rheumatol. 2001;20(6):406–410. doi: 10.1007/s100670170004. [DOI] [PubMed] [Google Scholar]
  47. van der Heijde D., Sharp J., Wassenberg S., Gladman D. D. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis. 2005 Mar;64 (Suppl 2):ii61–ii64. doi: 10.1136/ard.2004.030809. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES